BioMarin Announces Fourth Quarter and Full Year 2007 Financi...( Conference Call and Webcast to Be...)

Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET)

2007 Financial Highlights

- Total BioMarin revenue of $121.6 million

- Naglazyme net product revenue of $86.2 million, an increase of 85.4

percent over 2006 and above BioMarin's guidance range of $82 million

to $84 million

- Aldurazyme net product revenue of $123.7 million, an increase of 28.5

percent over 2006 and toward the upper end of BioMarin's guidance

range of $115 million to $125 million

- Net loss of $15.8 million, within the guidance range of a loss of $13

million to $18 million

- Net income of $2.6 million in the fourth quarter of 2007

2008 Financial Guidance

- Total BioMarin revenue in the range of $255 million to $306 million

which includes total product revenue of $213 million to $264 million

- Naglazyme net product revenue in the range of $105 million to $116

million

- Aldurazyme net product sales by Genzyme of $135 million to $145

million with net revenue to BioMarin from royalties and transfers of

inventory in the range of $68 million to $78 million

- Improved Kuvan net product revenue guidance in the range of $40

million to $70 million

- GAAP net income in the range of $20 million to $40 million and

non-GAAP net income in the range of $47 million to $67 million

NOVATO, Calif., Feb. 26 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2007. Net income was $2.6 million ($0.03 per share) for the fourth quarter of 2007, compared to a net loss of $10.4 million ($0.11 per share) for the fourth quarter of 2006. Net income for the fourth quarter of 2007 includes the receipt of the $15.0 million milestone payment from Merck Serono related to
'/>"/>